{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:10:14Z","timestamp":1791850214739,"version":"4.3.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.cca.2019.10.045","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T20:05:59Z","timestamp":1574712359000},"page":"234-240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["High-risk screening for Fabry disease in a Canadian cohort of chronic kidney disease patients"],"prefix":"10.1016","volume":"501","author":[{"given":"Christiane","family":"Auray-Blais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Lavoie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Abaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Boutin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayub","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adeera","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Mac-Way","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"TR Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2019.10.045_b0005","doi-asserted-by":"crossref","unstructured":"J.T.R. Clarke, Narrative review: Fabry disease, Ann. Intern. Med. 146(6) (2007) 425\u2013433. https:\/\/doi.org\/10.7326\/0003-4819-146-6-200703200-00007.","DOI":"10.7326\/0003-4819-146-6-200703200-00007"},{"key":"10.1016\/j.cca.2019.10.045_b0010","doi-asserted-by":"crossref","unstructured":"A. Toupin, P. Lavoie, M.F. Arthus, M. Abaoui, M. Boutin, C. Fortier et al., Analysis of globotriaosylceramide (Gb3) isoforms\/analogs in unfractionated leukocytes, B lymphocytes and monocytes from Fabry patients using ultra-high performance liquid chromatography\/tandem mass spectrometry, Anal. Chim. Acta. 1015 (2018) 35\u201349. https:\/\/doi.org\/10.1016\/j.aca.2018.02.022.","DOI":"10.1016\/j.aca.2018.02.022"},{"key":"10.1016\/j.cca.2019.10.045_b0015","doi-asserted-by":"crossref","unstructured":"P. Lavoie, M. Boutin, C. Auray-Blais, Multiplex analysis of novel urinary lyso-Gb3-related biomarkers for Fabry disease by tandem mass spectrometry, Anal. Chem. 85 (3) (2013) 1743\u20131752. https:\/\/doi.org\/10.1021\/ac303033v.","DOI":"10.1021\/ac303033v"},{"issue":"24","key":"10.1016\/j.cca.2019.10.045_b0020","doi-asserted-by":"crossref","first-page":"13382","DOI":"10.1021\/acs.analchem.7b03609","article-title":"Separation and analysis of lactosylceramide, galabiosylceramide, and globotriaosylceramide by LC-MS\/MS in urine of Fabry disease patients","volume":"89","author":"Boutin","year":"2017","journal-title":"Anal. Chem."},{"key":"10.1016\/j.cca.2019.10.045_b0025","doi-asserted-by":"crossref","unstructured":"W. Terryn, P. Cochat, R. Froissart, A. Ortiz, Y. Pirson, B. Poppe, A. et al. Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice, Nephrol. Dial. Transplant 28(3) (2013) 505\u2013517. https:\/\/doi.org\/10.1093\/ndt\/gfs526.","DOI":"10.1093\/ndt\/gfs526"},{"key":"10.1016\/j.cca.2019.10.045_b0030","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.cca.2019.10.045_b0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset Fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.cca.2019.10.045_b0040","doi-asserted-by":"crossref","unstructured":"H.Y. Lin, K.W. Chong, J.H. Hsu, H.C. Yu, C.C. Shih, C.H. Huang, Set al. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population, Circ. Cardiovasc. Genet. 2(5) (2009) 450\u2013456. https:\/\/doi.org\/10.1161\/CIRCGENETICS.109.862920.","DOI":"10.1161\/CIRCGENETICS.109.862920"},{"key":"10.1016\/j.cca.2019.10.045_b0045","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jpeds.2017.06.048","article-title":"Newborn screening for lysosomal storage disorders in Illinois: the initial 15-month experience","volume":"190","author":"Burton","year":"2017","journal-title":"J. Pediatr."},{"key":"10.1016\/j.cca.2019.10.045_b0050","unstructured":"Alberta Health Services (2017) Gene therapy used to treat Fabry disease \u2013 a world first, <https:\/\/www.albertahealthservices.ca\/news\/releases\/2017\/Page13691.aspx>."},{"key":"10.1016\/j.cca.2019.10.045_b0055","doi-asserted-by":"crossref","unstructured":"A. Mehta, J.T.R. Clarke, R. Giugliani, P. Elliot, A. Linhart, M. Beck, G. Sunder-Plassmann, Natural course of Fabry disease: changing pattern of causes of death in FOS \u2013 Fabry Outcome Survey, J. Med. Genet. 46 (2009) 548\u2013552. https:\/\/doi.org\/10.1136\/jmg.2008.065904.","DOI":"10.1136\/jmg.2008.065904"},{"key":"10.1016\/j.cca.2019.10.045_b0060","doi-asserted-by":"crossref","unstructured":"D. Doheny, R. Srinivasan, S. Pagant, B. Chen, M. Yasuda, R.J. Desnick, Fabry disease: prevalence of affected males and heterozygotes with pathogenic GLA mutations identified by screening renal, cardiac and stroke clinics, 1995\u20132017, J. Med. Genet. 55 (2018) 261\u2013268. https:\/\/doi.org\/10.1136\/jmedgenet-2017-105080.","DOI":"10.1136\/jmedgenet-2017-105080"},{"issue":"5","key":"10.1016\/j.cca.2019.10.045_b0065","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1159\/000494678","article-title":"Results of Fabry disease screening in male pre-end stage renal disease patients with unknown etiology found through the platform of a chronic kidney disease education program in a northern Taiwan medical center","volume":"43","author":"Lin","year":"2018","journal-title":"Kidney Blood Press. Res."},{"issue":"1","key":"10.1016\/j.cca.2019.10.045_b0070","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1080\/0886022X.2016.1254656","article-title":"Screening Fabry\u2019s disease in chronic kidney disease patients not on dialysis: a multicenter study","volume":"39","author":"Yeni\u00e7erio\u011flu","year":"2017","journal-title":"Ren. Fail."},{"issue":"6","key":"10.1016\/j.cca.2019.10.045_b0075","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1159\/000452605","article-title":"The prevalence of Fabry disease in patients with chronic kidney disease in Turkey: the TURKFAB study","volume":"41","author":"Turkmen","year":"2016","journal-title":"Kidney Blood Press. Res."},{"issue":"1","key":"10.1016\/j.cca.2019.10.045_b0080","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s10545-005-5263-4","article-title":"Measurement of urinary CDH and CTH by tandem mass spectrometry in patients hemizygous and heterozygous for Fabry disease","volume":"28","author":"Mills","year":"2005","journal-title":"J. Inherit. Metab. Dis."},{"issue":"11","key":"10.1016\/j.cca.2019.10.045_b0085","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/rcm.1948","article-title":"Rapid determination of urinary globotriaosylceramide isoform profiles by electrospray ionization mass spectrometry using stearoyl-d35-globotriaosylceramide as internal standard","volume":"19","author":"Fauler","year":"2005","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.cca.2019.10.045_b0090","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10545-009-1055-6","article-title":"Proposed high-risk screening protocol for Fabry disease in patients with renal and vascular disease","volume":"32","author":"Auray-Blais","year":"2009","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.cca.2019.10.045_b0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.15353\/cjo.74.550","article-title":"Improved ways to screen for patients with Fabry disease, involving optometry in a multidisciplinary approach","volume":"74","author":"Michaud","year":"2012","journal-title":"Can. J. Optometry"},{"issue":"4","key":"10.1016\/j.cca.2019.10.045_b0100","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","article-title":"Chronic kidney disease epidemiology collaboration, using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate","volume":"145","author":"Levey","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cca.2019.10.045_b0105","doi-asserted-by":"crossref","unstructured":"A.S. Levey, L.A. Stevens, C.H. Schmid, Y.L. Zhang, A.F. 3rd Castro, H.I. Feldman, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration), A new equation to estimate glomerular filtration rate, Ann. Intern. Med. 150(9) (2009) 604\u2013612.","DOI":"10.7326\/0003-4819-150-9-200905050-00006"},{"key":"10.1016\/j.cca.2019.10.045_b0110","doi-asserted-by":"crossref","first-page":"S263","DOI":"10.1016\/S0248-8663(10)70025-4","article-title":"Fabry disease: enzymatic screening using dried blood spots on filter paper","volume":"31","author":"Caudron","year":"2010","journal-title":"Rev. Med. Int."},{"key":"10.1016\/j.cca.2019.10.045_b0115","doi-asserted-by":"crossref","unstructured":"C. Auray-Blais, P. Lavoie, M. Boutin, M. Abaoui, High-Risk Screening for Fabry Disease: Analysis by Tandem Mass Spectrometry of Globotriaosylceramide (Gb3) in Urine Collected on Filter Paper, Curr. Protoc. Hum. Genet. 93 (2017) 17.26.1\u201317.26.12. https:\/\/doi.org\/10.1002\/cphg.34.","DOI":"10.1002\/cphg.34"},{"key":"10.1016\/j.cca.2019.10.045_b0120","doi-asserted-by":"crossref","unstructured":"P. Lavoie, M. Boutin, M. Abaoui, C. Auray-Blais, Fabry Disease Biomarkers: Analysis of Urinary Lyso-Gb3 and Seven Related Analogs Using Tandem Mass Spectrometry, Curr. Protoc. Hum. Genet. 90 (2016) 17.22.1\u201317.22.12. https:\/\/doi.org\/10.1002\/cphg.1.","DOI":"10.1002\/cphg.1"},{"key":"10.1016\/j.cca.2019.10.045_b0125","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0009-8981(81)90384-3","article-title":"Differential assay for lysosomal alpha-galactosidases in human tissues and its application to Fabry\u2019s disease","volume":"112","author":"Mayes","year":"1981","journal-title":"Clin. Chim. Acta."},{"issue":"3","key":"10.1016\/j.cca.2019.10.045_b0130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ymgme.2007.10.001","article-title":"Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease","volume":"93","author":"Auray-Blais","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"17","key":"10.1016\/j.cca.2019.10.045_b0135","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.4155\/bio-2016-0116","article-title":"Relative distribution of Gb3 isoforms\/analogs in NOD\/SCID\/Fabry mice tissues determined by tandem mass spectrometry","volume":"8","author":"Proven\u00e7al","year":"2016","journal-title":"Bioanalysis"},{"key":"10.1016\/j.cca.2019.10.045_b0140","doi-asserted-by":"crossref","unstructured":"M. Gaggl, M. Hofer, S. Weidner, J. Kleinert, G. Fauler, M. Wallner, P. et al. Interfering parameters in the determination of urinary globotriaosylceramide (Gb3) in patients with chronic kidney disease, J. Nephrol. 28 (2015) 679\u2013689. https:\/\/doi.org\/10.1007\/s40620-015-0193-1.","DOI":"10.1007\/s40620-015-0193-1"},{"key":"10.1016\/j.cca.2019.10.045_b0145","doi-asserted-by":"crossref","unstructured":"R. Schiffmann, S. Forni, C. Swift, N. Brignol. X. Wu, D.J. Lockhart et al. Risk of death in heart disease is associated with elevated urinary globotriaosylceramide, J. Am. Heart Assoc. 3(1) 2014. https:\/\/doi.org\/10.1161\/JAHA.113.000394.","DOI":"10.1161\/JAHA.113.000394"},{"key":"10.1016\/j.cca.2019.10.045_b0150","doi-asserted-by":"crossref","unstructured":"R.Schiffmann, D.A. Hughes, G.E. Linthorst, A. Ortiz, E. Svarstad, D.G. Warnock, M.L. West, C. Wanner, Conference Participants, Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201cKidney Disease: Improving Global Outcomes\u201d (KDIGO) Controversies Conference, Kidney Int. 91(2) (2017) 284\u2013293. https:\/\/doi.org\/10.1016\/j.kint.2016.10.004.","DOI":"10.1016\/j.kint.2016.10.004"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119321096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898119321096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T14:52:43Z","timestamp":1757861563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898119321096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":30,"alternative-id":["S0009898119321096"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2019.10.045","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-risk screening for Fabry disease in a Canadian cohort of chronic kidney disease patients","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2019.10.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}